Next-Generation Incretin Pipeline 2026

The shape of the landscape

“Next-generation incretin pipeline” is an umbrella description, not a claim that these programs share one molecular class. Three use injected peptide-based approaches; orforglipron is an oral small molecule. Only retatrutide is a true GLP-1 / GIP / glucagon triagonist.

The receptor families that matter:

• GLP-1 — incretin; suppresses appetite, slows gastric emptying, augments insulin secretion
• GIP — incretin; complements GLP-1 effects, may improve GI tolerability of co-agonists
• Glucagon — increases energy expenditure and hepatic fat clearance
• Amylin — adjacent to GLP-1; reduces appetite and slows gastric emptying through a separate pathway

At a glance

Reta — the triagonist anchor

Reta — retatrutide (LY-3437943) — is the only molecule on this page designed to activate GLP-1, GIP and glucagon receptors. In the TRIUMPH-1 Phase 3 master trial, Lilly reported a 28.3% efficacy-estimand mean change at the 12 mg study dose over 80 weeks. This was a company topline disclosure dated 21 May 2026, not a head-to-head comparison with the other programs.

On 23 July 2026, Lilly reported additional sponsor topline results: up to 20.8% mean body-weight reduction at 80 weeks in TRIUMPH-2, which enrolled adults with obesity or overweight and type 2 diabetes, and up to 22.6% in TRIUMPH-3, which enrolled adults with severe obesity and established cardiovascular disease with or without type 2 diabetes. Both figures describe the 12 mg study arm under the efficacy estimand. Lilly said it planned a US biologics license application in the first quarter of 2027.

The Remy Peptides retatrutide research profile keeps the compound identity, receptor design and evidence boundaries together in one reference.

Retatrutide remains investigational. Across the cited Phase 3 releases, gastrointestinal adverse events were the most common event class. Detailed peer-reviewed Phase 3 reporting should be distinguished from sponsor topline releases as it becomes available.

For batch-level Reta evidence, the COA archive lists published Janoshik task IDs and verification keys, and the versioned dataset makes the same records machine-readable.

CagriSema — the amylin combination

CagriSema is not a triagonist molecule; it is a fixed-dose co-formulation of cagrilintide (an amylin analogue) and semaglutide (a GLP-1 agonist) developed by Novo Nordisk. The combination studies complementary receptor pathways, but comparative efficacy and tolerability cannot be inferred outside its own trial design.

Novo Nordisk reported a 22.7% efficacy-estimand mean change at 68 weeks in REDEFINE-1 and 20.4% under the treatment-policy estimand. The company submitted a US NDA in December 2025. CagriSema was not US-approved at this page's review date.

The Remy Peptides CagriSema research profile keeps the cagrilintide/semaglutide co-formulation design and REDEFINE trial readouts together in one reference.

Survodutide — the dual GLP-1 / glucagon

Survodutide (BI 456906) is a dual GLP-1 / glucagon agonist from Boehringer Ingelheim and Zealand Pharma. Skips the GIP receptor that tirzepatide and reta both hit. The GLP-1 + glucagon combination is the same pair reta uses minus GIP — testing whether GIP is necessary or whether GLP-1 + glucagon alone is enough.

Boehringer Ingelheim reported a 16.6% efficacy-estimand mean change at 76 weeks in the Phase 3 SYNCHRONIZE-1 trial. Survodutide remained investigational, with additional Phase 3 programs covering metabolic and liver-disease endpoints.

The Remy Peptides survodutide research profile covers the SYNCHRONIZE Phase 3 programme and the dual GLP-1 / glucagon evidence in one reference.

Orforglipron — the oral outlier

Orforglipron is the structural and regulatory outlier: an oral small-molecule GLP-1 receptor agonist, not an injected peptide. Lilly reported a 12.4% efficacy-estimand mean change at 72 weeks in ATTAIN-1. The FDA approved orforglipron in the United States on 1 April 2026.

The Remy Peptides orforglipron research profile tracks the ATTAIN readouts and the oral small-molecule design in one reference.

Where this leaves the field

Retatrutide is the only triagonist in this set. CagriSema, survodutide and orforglipron answer different molecular and regulatory questions, so their trial percentages should not be ranked as if they came from one protocol. The most decision-useful comparison is class, trial design, source date and current approval status.

Primary sources and last review

• TRIUMPH-1 topline results, Lilly (21 May 2026) and trial registry
• TRIUMPH-2 and TRIUMPH-3 topline results, Lilly (23 July 2026), with TRIUMPH-2 and TRIUMPH-3 trial registries
• REDEFINE-1 and CagriSema NDA disclosure, Novo Nordisk (18 December 2025) and trial registry
• SYNCHRONIZE-1 topline results, Boehringer Ingelheim (28 April 2026) and trial registry
• ATTAIN-1 topline results, Lilly (7 August 2025) and FDA approval (1 April 2026)

Last reviewed: 28 July 2026. Figures are labeled by sponsor estimand and remain indirect across programs.

Follow the changing readouts and regulatory milestones in the Remy Peptides 2026 obesity-drug pipeline timeline.

For the separate US supply boundary after the shortage ended, continue to the 2026 GLP-1 compounding landscape.

For research-context comparison of reta specifically against tirzepatide (the current GLP-1 / GIP standard), see Reta vs Tirzepatide.